The purpose of the present study was to investigate the effects on blood pressure and myocardial hypertrophy in SHRs (spontaneously hypertensive rats) of RNAi (RNA interference) targeting ACE (angiotensin-converting enzyme). SHRs were treated with normal saline as vehicle controls, with Ad5-EGFP as vector controls, and with recombinant adenoviral vectors Ad5-EGFP-ACE-shRNA, carrying shRNA (small hairpin RNA) for ACE as ACE-RNAi. WKY (Wistar-Kyoto) rats were used as normotensive controls treated with normal saline. The systolic blood pressure of the caudal artery was recorded. Serum levels of ACE and AngII (angiotensin II) were determined using ELISA. ACE mRNA and protein levels were determined in aorta, myocardium, kidney and lung. On day 32 of the experiment, the heart was pathologically examined. The ratios of heart weight/body weight and left ventricular weight/body weight were calculated. The serum concentration of ACE was lower in ACE-RNAi rats (16.37 + − 3.90 ng/ml) compared with vehicle controls and vector controls (48.26 + − 1.50 ng/ml and 46.67 + − 2.82 ng/ml respectively; both P < 0.05), but comparable between ACE-RNAi rats and WKY rats (14.88 + − 3.15 ng/ml; P > 0.05). The serum concentration of AngII was also significantly lower in ACE-RNAi rats (18.24 + − 3.69 pg/ml) compared with vehicle controls and vector controls (46.21 + − 5.06 pg/ml and 44.93 + − 4.12 pg/ml respectively; both P < 0.05), but comparable between ACE-RNAi rats and WKY rats (16.06 + − 3.11 pg/ml; P > 0.05). The expression of ACE mRNA and ACE protein were significantly reduced in the myocardium, aorta, kidney and lung in ACE-RNAi rats compared with that in vehicle controls and in vector controls (all P < 0.05). ACE-RNAi treatment resulted in a reduction in systolic blood pressure by 22 + − 3 mmHg and the ACE-RNAi-induced reduction lasted for more than 14 days. In contrast, blood pressure was continuously increased in the vehicle controls as well as in the vector controls. The ratios of heart weight/body weight and left ventricular weight/body weight were significantly lower in ACE-RNAi rats (3.12 + − 0.23 mg/g and 2.24 + − 0.19 mg/g) compared with the vehicle controls (4.29 + − 0.24 mg/g and 3.21 + − 0.13 mg/g; P < 0.05) and the vector controls (4.43 + − 0.19 mg/g and 3.13 + − 0.12 mg/ g; P < 0.05). The conclusion of the present study is that ACE-silencing had significant antihypertensive effects and reversed hypertensive-induced cardiac hypertrophy in SHRs, and therefore RNAi might be a new strategy in controlling hypertension.
INTRODUCTION
Hypertension is an important risk factor of congestive heart failure, stroke and kidney failure. According to the statistics of the WHO (World Health Organization), 15-37 % of adults have hypertension. The prevalence of hypertension even increases to 50 % in those of over 60 years of age. It is estimated that the number of hypertensive patients across the world will go up to 1.5 billion in 2025; however, only one-third of patients have been treated successfully. The main reasons why the hypertension control rate is so low are: (i) hypertension is a lifelong disease, but nearly all antihypertensive drugs have a short half-life and some kinds of side effects; and (ii) compliance is one of the problems in the control of hypertension. The antihypertensive effects of most drugs last for less than 24 h [1] . Hence, patients have to take medicine every day, which makes it hard for patients to comply. Moreover, the non-specific effects and side effects of these drugs are relatively higher. Therefore a therapy with long-term effects and less side effects is desirable for a disease requiring lifelong treatment.
RNAi (RNA interference)-mediated siRNA (short interfering RNA) represents a recent breakthrough in effective blocking of the target genes in mammalian cells. As a kind of dsRNA (double-stranded RNA) with 21-23 nucleotides in each strand, siRNA is capable of specifically degrading the target mRNA to effectively inhibit the subsequent protein expression, but avoids non-specific degradation of genes and long dsRNAmediated cell death. Compared with single-stranded antisense nucleotides, the effects of siRNA on mRNA degradation are more efficient and specific, only a much lower concentration of siRNA is needed. This approach is therefore widely applied to studies in gene therapy [2] [3] [4] [5] [6] [7] .
ACE (angiotensin-converting enzyme) has been shown to play an important role in the pathogenesis of hypertension. The antihypertensive effects of ACE inhibitors have been very well-documented both in animal models and in humans. In the present study we hypothesized that ACE-RNAi would result in longterm BP (blood pressure) control as well as improving high BP-induced cardiac complications. We tested our hypothesis in SHRs (spontaneous hypertensive rats) with ACE-specific shRNA (small hairpin RNA).
METHODS

Materials
Recombinant adenoviral vectors (Ad5-EGFP-ACEshRNA; where EGFP is enhanced green fluorescent protein) and its corresponding control vector (Ad5-EGFP) were tested for TCID 50 (50 % tissue culture infective dose)/ml, and 7 × 10 9 and 6.3 × 10 9 were selected as the test doses respectively. These virus vectors were all constructed by the BenYuan ZhengYang Company (Beijing, China). The RNAi target sequence of ACE mRNA (GenBank ® accession number NM_012544) was 5 -AACCTAACATGTCAGCCTCTG-3 . Other materials and chemicals were obtained from commercial sources.
Animal preparation
The study was approved by the Animal Welfare Committee at the Second Hospital of Shanxi Medical University of China. All procedures conformed to the principles and the laws of the Chinese Central Government. Experiments were carried out on 36 male SHRs and 12 agematched male WKY (Wistar-Kyoto) rats. The animals were kept at room temperature (25
• C) with a 12 h/12 h dark (18:00-06:00 h)/light (06:00-18:00 h) cycle. The rats were fed with pelleted rat chow and water ad libitum.
Study protocol
The 36 12-week-old SHRs were randomly divided into three groups (n = 12 for each group), the vehicle controls were injected intravenously with normal saline (500 μl), the vector controls with Ad5-EGFP (500 μl) and the ACE-RNAi group received intravenous Ad5-EGFP-ACE-shRNA (500 μl). WKY rats received normal saline (500 μl) intravenously. All rats had two injections on day 1 and day 16 during the experiment. Before and after injection, SBP (systolic BP) of the caudal artery was recorded. On day 3 of the experiment, ACE mRNA and protein expressions were evaluated in the myocardium, aorta, kidney and lung with RT (reverse transcription)-PCR and Western blot analysis. Serum concentrations of ACE and AngII (angiotensin II) were measured by ELISA. On day 32 of the experiment, the rats were killed with a guillotine. Pathological examination of the heart was performed. The ratios of HW (heart weight)/BW (body weight) and LVW (left ventricle weight)/BW were calculated.
RT-PCR
Total RNA was extracted from the myocardium, aorta, kidney and lung of the rat. The RNA concentration was quantified by spectroscopy. Total RNA (5 μg) was incubated with avian myeloblastosis virus reverse transcriptase in a mixture containing deoxynucleotides, random primer and RNase inhibitor at 42
• C for 60 min. cDNA was amplified in a final volume of 50 μl containing 0.5 μl of gene-specific primers, 1 μl of 10 mM deoxynucleotides, 4 μl of 2.5 mM MgCl 2 , 2 μl of Taq polymerase and 10 μl of RNA sample. Primer sequences for ACE were as follows [8] : forward primer 5 -CAAAAGCTGCG-AAGGATCCATCGG-3 and reverse primer 5 -CC-ATGTCGTAAATGTTCTCCCAGC-3 , yielding an amplification product of 547 bp. The housekeeping transcript GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as a positive control. The primers for GAPDH were: forward primer 5 -TCCC-TCAAGATTGTCAGCAA-3 and reverse primer 5 -AGATCCACAACGGATACATT-3 , yielding an amplification product of 308 bp. Amplification was conducted with a denaturing step at 94
• C for 30 s; annealing at 58
• C for 30 s and elongation at 72
• C for 30 s for 36 cycles; and a final elongation step at 72
• C for 10 min. PCR products were separated on a 10 % (w/v) agarose gel and bands intensities were quantified with an image acquisition and analysis system (Gel Doc XR170-8170; Bio-Rad).
Western blot assay
Protein (50 μg) was separated by SDS/PAGE (8 % gels). Proteins were transferred on to nitrocellulose membranes by electroblotting. The membranes were blocked with 0.1 % BSA for 2 h at room temperature, and then incubated overnight with mouse anti-rat ACE antibody (1:500) or mouse anti-rat β-actin antibody (1:5000) at 4
• C. After washing with TBS-T [Tris-buffered saline (10 mM Tris/HCl, pH 7.5 and 150 mM NaCl) containing 0.05 % Tween 20] three times (each for 5 min), the membranes were incubated for 2 h with a sheep antimouse IgG antibody (1:10000) at room temperature, and then rinsed three times with TBS-T. The blots were developed by ECL (enhanced chemiluminescence) and exposed to X-ray film, and quantification was performed with an image acquisition and analysis system (Gel Doc XR170-8170; Bio-Rad). The result was presented as the ratio of ACE/β-actin.
Measurement of serum concentrations of ACE and AngII
Under ether anaesthesia, blood was collected from the abdominal aorta, and the plasma and cells were separated by centrifugation. The plasma was stored at − 80
• C. ACE and AngII levels were determined using ELISA (Adlitteram Diagnostic Laboratories) according to the manufacturer's protocol.
HW and LVW
Whole heart was weighed and the left ventricle was isolated and weighed. The ratios of whole HW/BW and LVW/BW were calculated. Partial myocardium was sectioned and mounted into paraffin slices, stained with HE (haemotoxylin/eosin), and observed under a light microscope.
Statistical analysis
Values are reported as means + − S.D. The comparisons of BP and heart rate were determined with repetitive measurement and ANOVA. The multiple comparisons of various groups were performed with SNK (StudentNewman-Keuls). The multiple comparisons of various time points of a group were performed with a Dunnett's test. One-way ANOVA was used for various group comparisons of other indexes. Data analysis was performed using the Statistical Package for Social Science (SPSS 13.0). Differences were considered significant when P < 0.05.
RESULTS
Effects of ACE-RNAi on BP
The SBP (mean + − S.D.) before intervention was 190 + − 4 mmHg for SHR vehicle controls, 189 + − 3 mmHg for SHR vector controls, 190 + − 5 mmHg for ACE-RNAi SHRs and 113 + − 4 mmHg for WKY rats. No significant difference was found among the SHR groups (P > 0.05). On day 3 of the experiment, the SBP of the ACE-RNAi group was significantly reduced by 19 + − 3 mmHg, and on day 13 by 22 + − 3 mmHg. After the second injection, the SBP was significantly reduced to 38 + − 4 mmHg compared with the basal level. The antihypertensive effect lasted for more than 14 days after each injection; however, both vehicle and vector controls had a continued increase in BP (Figure 1 ).
ACE mRNA levels
ACE mRNA expression in the myocardium, aorta, kidney and lung was significantly decreased in the ACERNAi SHRs compared with that in the vehicle controls and the vector controls (all P < 0.05), and were comparable between ACE-RNAi SHRs and WKY rats (P > 0.05) (Figure 2 ).
ACE protein levels
To determine whether protein expression was similar to mRNA expression, we measured the ACE protein level with Western blot analysis in the myocardium, aorta, kidney and lung. ACE protein levels were also significantly decreased in the ACE-RNAi group compared with that in the vehicle controls and vector controls (all P < 0.05), and were similar to that of WKY rats (P > 0.05) (Figure 3 ).
Serum concentrations of ACE and AngII
The serum ACE concentration in the ACE-RNAitreated SHRs (16.37 ng/ml + − 3.01 ng/ml) was significantly lower than that in SHR vehicle controls and vector controls (48.26 + − 3.69 ng/ml and 46.67 + − 3.92 ng/ml respectively; both P < 0.05), and was similar to that in WKY rats (14.88 + − 3.15 ng/ml; P > 0.05). The serum AngII concentration was also significantly lower in ACE-RNAi rats (18.24 pg/ml + − 3.69 pg/ml) than in vehicle controls and vector controls (46.21 + − 5.06 pg/ml and 44.93 + − 4.12 pg/ml respectively; both P < 0.05), as was the concentration in WKY rats (16.06 + − 3.11 pg/ml; P < 0.05) ( Table 1 ).
The ratios of HW/BW and LVW/BW
The ratios of HW/BW and LVW/BW of ACE-RNAitreated SHRs (3.12 + − 0.23 mg/g and 2.24 + − 0.19 mg/g respectively) were significantly lower than that in SHR vehicle controls (4.29 + − 0.24 mg/g and 3.21 + − 0.13, mg/g; both P < 0.05) and vector controls (4.43 + − 0.19 mg/g and 3.13 + − 0.12 mg/g; both P < 0.05), but higher than those in WKY rats (2.85 + − 0.13 mg/g and 2.06 + − 0.11 mg/g; both P < 0.05) ( Table 2 ).
Pathological changes
Under the light microscope, cardiac muscle cell hypertrophy was observed in SHR vehicle controls and SHR vector controls. A significant improvement in cardiac hypertrophy was identified in ACE-RNAi SHRs (Figure 4) .
DISCUSSION
The present study showed that RNAi could effectively reduce the BP of SHRs. The antihypertensive effect lasted for more than 2 weeks after a single injection, with favourable effects on hypertension-induced cardiac hypertrophy. The antihypertensive effects might be related to the ACE silencing.
It has long been known that the activation of the RAS (renin-angiotensin system) contributes to high BP. RAS has also been known as the target for hypertension control. Both ACE inhibitors and angiotensin receptor blockers have been widely used as antihypertensive drugs in daily clinical practice. It is well-known that these drugs have organ protection effects independent of their antihypertensive effects, especially on the cardiovascular system; however, owing to their short-acting duration, patients have to take them every day. This inconvenience leads to poor patient compliance. Galli, Phillips and coworkers [9] [10] [11] [12] have employed antisense nucleotide technology to inhibit AT 1 R (AngII type 1 receptor) expression in hypertensive rats, leading to an overt antihypertensive effect, but the application of this technique is limited owing to its low success rate, high cost, short-lasting duration and unsatisfactory specificity.
The post-transcriptional gene-silencing phenomenon is evolutionarily conserved. RNAi is a gene-silencing phenomenon discovered in the last 10 years. This discovery creates a new gene down-regulation technique. RNAi, triggered by dsRNA, features high specificity, only degrading mRNA with sequence homology. Compared with gene knockout, RNAi has the advantages of short cycle and low cost. Relative to the antisense nucleotide technique, RNAi has high efficiency, strong specificity and long-lasting duration. It has been widely applied in the study of gene function in mammals [13] , as well as in the treatment of cancer [14, 15] , virus-infected diseases [16] [17] [18] [19] and monogenetic disorders [20] .
In recent years, inhibiting AT 1 R expression by RNAi has been employed to study the functional consequence of AT 1 R silencing [21] [22] [23] [24] . Most of these studies were performed in vitro [21, 22] , and very few in vivo [23, 24] . In vitro in vascular smooth muscle cells and in cultured cardiac muscle cells, Zhang et al. [23] report that effective down-regulation of AT 1a R expression by RNAi can effectively lower the BP in a 2K1C hypertensive rat model. By injecting adenovirus-mediated AT 1a R-shRNA into the stem nucleus tractus solitarius/dorsal vagal nucleus of the brain in C57BL mice, Chen et al. [24] have found that the nocturnal BP fell significantly, suggesting that RNAi-ACE might lower BP. We tested whether BP and cardiac hypertrophy would respond to ACE silencing by administration of adenovirus vectors of ACERNAi through the tail vein in SHRs. As a gene-transfer vector, the adenovirus vector with high transfection efficiency and not being integrated into the host genome has been widely used in RNAi-related studies [25] [26] [27] [28] .
In addition to the antihypertensive effect of ACE silencing, we also found that the expression of ACE was suppressed in myocardium, aorta, kidney and lung, and the serum level of ACE was significantly decreased in ACERNAi SHRs compared with the two groups of ACE- unsilenced SHRs, indicating that Ad5-EGFP-ACEshRNA effectively silenced ACE gene expression in vivo and ACE silencing resulted in long-term BP lowering.
Cardiac hypertrophy is one of the major hypertensioninduced pathological consequences in heart. Cardiac hypertrophy is often manifested as an increase in the ratios of HW/BW and LVW/BW at its early developing phase. We observed that ACE silencing could reverse the hypertension-induced cardiac hypertrophy in SHRs, as indicated by dramatically reducing the ratios of HW/BW and LVW/BW in SHRs treated with Ad5-EGFP-ACEshRNA, but not in those groups of non-ACE-silencing SHRs. Even though we did not know whether the improvement in cardiac hypertrophy was related to ACE silencing or secondary to BP reduction, it has long been known that RAS plays a very important role in the regulation of growth and proliferation of cardiac myocytes. ACE inhibitors have been successfully shown to reverse hypertension-induced cardiac hypertrophy, independent of their antihypertensive effects [29] [30] [31] [32] . The blockade of AngII production with ACE inhibitors has been shown to significantly lower BP with efficient regression of cardiac hypertrophy in both hypertensive animal models and human clinical trials [33, 34] . In the present study we have shown that RNAi-induced ACE silencing could reduce the transformation of AngI to AngII. However whether it could become a new generation of antihypertensive therapy needs to be further explored.
Limitations
Because the adenovirus vector cannot be integrated into the host genome it has low genetic and immune toxicity; however, this potential hazard should still make us cautious of it clinical use, and the safety of the gene-transfer vector is still the biggest challenge of gene therapy. A further limitation is that in the present study the antihypertensive effect of RNAi lasted only approx. 14 days, which limited its clinical application.
Conclusion
In conclusion, ACE silencing had significant antihypertensive effects and could reverse hypertensive-induced cardiac hypertrophy in SHRs, so RNAi might be a new strategy in controlling hypertension.
